Kanyos Bio: Anokion Announces Appointment of Dr. John Hohneker as Chief Executive Officer
Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the appointment of John Hohneker, M.D., as president and chief executive officer, effective January 22.
Read full article »
Kanyos develops and provides immune tolerance therapies for autoimmune diseases such as type-1 diabetes and celiac disease.
Read more